You are here

  • Home
  • Archive
  • Volume 69, Issue 2
  • Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Finckh A, Ciurea A, Brulhart L, et al
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Annals of the Rheumatic Diseases 2010;69:387-393.